Floatz logo

cc-115

Ewing's Osteosarcoma

CelgeneSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

57 Active assets in the Ewing's Osteosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Milton S. Hershey Medical Center
Phase 3BB
Nivolumab
Children's National Research Institute
Phase 2B
Cyclophosphamide
Essen Biotech
Phase 2B
Hycamtin
Pfizer
Phase 2B
Inno-206
Children's National Research Institute
Phase 2B

View all 50 →

Same molecule, other indications

cc-115 is also rated in:

glioblastomaDormant
CCC
Indicative ·
52 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →